Form 10-K Summary
Filing entity and period: The provided filing is for Experience Investment Corp., not Strata Critical Medical, Inc. It covers the fiscal period from May 24, 2019, the date of incorporation, through December 31, 2019. The filing is an annual report, not a standalone 2019 fourth-quarter report.
Business Context
Experience Investment Corp. was an early-stage blank check company, or SPAC, formed to identify and complete an initial business combination. It had no operating business, employees, or operating revenue as of December 31, 2019. Management intended to focus primarily on targets in the travel and leisure industry, generally with transaction values between $500 million and $2.0 billion.
The company completed its initial public offering on September 17, 2019, selling 27.5 million units at $10.00 per unit. Its units began trading on September 13, 2019, and its Class A common stock and warrants began trading on November 1, 2019, under the symbols EXPCU, EXPC, and EXPCW.
Financial Position and Results
| Metric | Amount |
|---|---|
| Operating revenue | None |
| Net income, inception through December 31, 2019 | $784,778 |
| Interest income on trust investments | $1,261,596 |
| Operating and formation costs | $268,206 |
| Income tax provision | $208,612 |
| Net cash used in operating activities | $256,512 |
| Trust account investments | $276,261,596 |
| Cash outside the trust account | $1,305,608 |
| Total assets | $277,692,204 |
| Total liabilities | $9,996,306 |
| Deferred underwriting fee payable | $9,625,000 |
| Stockholders’ equity | $5,000,008 |
The reported net income was generated by interest earned on trust-account investments and did not reflect operating profitability. Basic and diluted net income per share was reported as $(0.01) after adjusting for income attributable to redeemable public shares.
The company had no long-term debt, capital leases, operating lease obligations, or off-balance-sheet arrangements. The trust account primarily held U.S. Treasury bills or money market investments investing in U.S. Treasury obligations. Management stated that interest-rate risk was not material because of the short-term nature of these investments.
Material Changes and Capitalization
- The company raised gross IPO proceeds of $275.0 million and received $7.5 million from the sale of 5.0 million private placement warrants.
- Approximately $276.3 million was held in the trust account at year-end, including approximately $1.3 million of interest income.
- At December 31, 2019, 26,180,927 Class A shares were subject to possible redemption at an aggregate redemption value of $262.7 million.
- The sponsor held 6,875,000 Class B founder shares, representing 20% of outstanding common stock and generally convertible into Class A shares upon completion of a business combination.
- Public and private warrants represented potential dilution for up to 14,166,667 Class A shares, generally at an exercise price of $11.50 per share.
- No comparable prior-year operating period exists because the company was incorporated in May 2019.
Outlook, Risks, and Unusual Items
The company expected to generate no operating revenue until after completing an initial business combination. It had until September 17, 2021 to complete that transaction. If unsuccessful, it would cease operations, redeem public shares from the trust account, and liquidate; the warrants would expire worthless. Based on the December 31, 2019 trust balance, management estimated a potential liquidation or redemption value of approximately $10.03 per public share, although the actual amount could be lower.
- Completion of a business combination was uncertain and depended on identifying an appropriate target, completing due diligence, obtaining financing if necessary, and satisfying transaction conditions.
- Public stockholders could redeem shares, potentially reducing cash available for a transaction and making it harder to satisfy target-company closing requirements.
- The company had not secured third-party financing and sponsor or management loans were discretionary rather than committed.
- Third-party creditor claims, bankruptcy proceedings, or unenforceable trust-account waivers could reduce amounts available to public stockholders. Sponsor indemnification was not independently verified and might not be sufficient.
- The sponsor, officers, and directors held founder shares, agreed to vote in favor of a proposed business combination if a vote occurred, and had fiduciary or contractual obligations to other entities, creating potential conflicts of interest.
- Additional equity or debt financing could materially dilute public stockholders or increase leverage.
- The company could complete a transaction without a public stockholder vote in certain circumstances, limiting stockholders’ ability to reject a target other than through redemption rights.
- The filing identified the emerging COVID-19 outbreak as a potential risk to travel and leisure targets, negotiations, valuations, and the timing of a business combination.
- Marcum LLP issued an unqualified audit opinion on the financial statements. Management reported effective disclosure controls, but the filing did not include an internal-control effectiveness assessment or auditor attestation because of applicable transition provisions for newly public companies.
Investor Verification Checklist
- Confirm the issuer identity: the supplied filing is for Experience Investment Corp., whereas the request metadata names Strata Critical Medical, Inc.
- Verify whether the intended reporting period is the inception-to-December 31, 2019 period rather than a fourth-quarter filing.
- Review the trust-account balance, redemption terms, deferred underwriting fee, and the September 17, 2021 business-combination deadline.
- Assess the dilution implications of the founder shares, public warrants, private placement warrants, and any potential future financing.
- Review sponsor indemnification limitations and the risk that creditor or bankruptcy claims could reduce redemption proceeds.
- Confirm any subsequent business-combination announcements or amendments filed after March 20, 2020, which are not reflected in this filing.